Collaboration - May 11, 2022
Novo Nordisk and Flagship Pioneering collaborate
The two companies have announced a collaboration to create a portfolio of novel research programmes to develop transformational medicines. The collaborators will explore opportunities to apply Flagship’s bioplatforms, an ecosystem that currently comprises 41 companies, to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these. A new […]
Pharma Business - April 26, 2022
Novo Nordisk receives positive scientific opinion from EMA
The European Medicines Agency (EMA) has granted the company a positive scientific opinion for a proposed update to the storage conditions of two human insulins. EMA’s positive scientific opinion will now be used to support obtaining approval of the more flexible storage conditions by national health authorities in a number of relevant low- and middle-income […]
New Market - April 4, 2022
Novo Nordisk’s Ozempic 2.0 mg approved in the US
Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved a 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analogue for the treatment of adults with type 2 diabetes. Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the […]
Collaboration - March 9, 2022
Novo Nordisk expands research collaboration in oral drug delivery technologies
Novo Nordisk has announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH). Since 2015, scientists from Novo Nordisk and the laboratories of Prof. Giovanni Traverso and Prof. Robert Langer have explored novel technologies as alternatives to syringes and […]
Pharma Business - December 17, 2021
Novo Nordisk announces supply challenges for Wegovy in the US
Novo Nordisk has announced that a contract manufacturer filling syringes for Wegovy pens for the US market has temporarily stopped deliveries and manufacturing following issues with Good Manufacturing Practices. As a consequence, Novo Nordisk does not expect to be able to meet demand in the US in the first half of 2022 and few new […]
Pharma Business - December 13, 2021
Novo Nordiskt to invest more than 17 billion DKK in manufacturing facilities
Novo Nordisk has announced plans to invest more than 17 billion Danish kroner in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark. The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to […]
